Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences Inc is experiencing robust growth in its leading product Ingrezza, which has demonstrated double-digit prescription growth year-over-year, positioning the company to potentially achieve sales of approximately $3 billion by 2028. The strong performance of Crenessity, currently capturing about 10% of the classical congenital adrenal hyperplasia market with a significant demand among pediatric and adult patients, bolsters the outlook for peak revenues exceeding $1 billion by 2030. Additionally, the company's well-structured pipeline includes multiple late-stage and early-stage assets that are expected to drive substantial long-term growth, with guidance indicating continued revenue growth through 2026.

Neurocrine Biosciences experienced a notably disappointing fourth quarter of 2025, reporting a non-GAAP EPS of $1.88, falling short of consensus estimates of $2.31, alongside an adjustment of FY26 Ingrezza revenue expectations due to a projected net price decline of approximately 5%. Competition poses a significant risk to the company's growth prospects, as the market share for Ingrezza in tardive dyskinesia may stagnate and the Huntington's disease chorea market is already being served by two existing products, limiting potential growth. Additionally, heightened R&D expenses have been anticipated to persist through 2028, indicating a longer timeline for achieving profitability and further dampening outlook for the company's financial health.